Pentoxifylline as an Adjunct Therapy for Patients With Eisenmenger Syndrome
Recruiting
N/A
Interventional Study
Eisenmenger Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 10 – 80
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 48 (estimated)
- Sponsor
- University of Sao Paulo General Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The Eisenmenger syndrome corresponds to the most advanced form of pulmonary arterial hypertension associated with congenital heart disease. The syndrome causes chronic hypoxemia, with an increase in erythrocyte mass, which predisposes to thrombotic complications. Pentoxifylline is a xanthine derivative and it is considered as a hemorrheological agent with described effects of reduction in erythroc…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Eisenmenger syndrome in functional class II, III or IV (World Health Organization for Pulmonary Hypertension).
2. Using or not oral anticoagulation with warfarin.
Exclusion Criteria:
1. Hospitalized.
2. History of relevant and/or repetitive bleeding.
3. Relevant comorbiditi…
Contacts